Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
News about Daré Bioscience, Inc. (NASDAQ: DARE) centers on its efforts to advance and commercialize women’s health products across contraception, sexual health, vaginal health and menopause. Company press releases highlight progress on clinical programs, grant-funded research, regulatory interactions and commercialization plans for both prescription and consumer health offerings.
Recent news has focused on DARE to PLAY Sildenafil Cream, a proprietary topical arousal cream designed specifically for women. Daré reports that this first-of-its-kind topical sildenafil formulation for women has been evaluated in multiple clinical studies and is being introduced via a Section 503B outsourcing facility as an evidence-backed option to enhance genital blood flow and arousal response. Updates describe pre-order availability in select U.S. states, webinar events with sexual health clinicians and the role of DARE to PLAY in the company’s broader 503B compounding strategy.
Another major news theme is Ovaprene, Daré’s investigational hormone-free monthly intravaginal contraceptive. Releases discuss interim Phase 3 results, data safety monitoring board recommendations to continue the pivotal study without modification, and the return of commercialization rights to Daré from a prior license partner. These items provide context on clinical progress, safety and tolerability findings, and the company’s plans to maximize the asset’s value.
Daré’s news flow also covers non-dilutive grant funding and collaborations, including multi-year support for DARE-LARC1, a long-acting contraceptive based on the DARE-IDDS programmable drug delivery platform, and grants for non-hormonal intravaginal contraceptive research and HPV-related programs. Corporate updates detail quarterly financial results, Nasdaq listing matters, and strategic initiatives that combine near-term revenue opportunities with long-term pipeline development. Investors and observers can use the DARE news page to follow these developments and track how clinical, commercial and funding milestones evolve over time.
Daré Bioscience (NASDAQ:DARE) reported Q2 2025 financial results and provided significant updates on its women's health product pipeline. The company is preparing to launch DARE to PLAY™ Sildenafil Cream in Q4 2025 through a 503B compounding pathway, marking its first revenue-generating product. The company reported $5.0 million in cash with a working capital deficit of $12.6 million, but strengthened its position post-quarter with $17.6 million from stock sales and a $6.0 million grant.
Key developments include positive interim results for Ovaprene® Phase 3 study, advancement of grant-funded programs for HPV treatment and long-acting contraception, and plans to commercialize vaginal probiotics and hormone therapy products. R&D expenses decreased 71% year-over-year to $1.4 million, while G&A expenses remained stable at $2.4 million.
Daré Bioscience (NASDAQ: DARE), a biopharmaceutical company focused on women's health solutions, has scheduled its Q2 2025 financial results conference call and webcast for August 14, 2025 at 4:30 p.m. ET.
Investors can join via phone at (646) 307-1963 or toll-free at (800) 715-9871 using conference ID 2684883. The webcast will be available on the company's investor relations website and archived until August 28, 2025.
Daré Bioscience (NASDAQ: DARE) and Rosy Wellness have announced the launch of a consumer awareness campaign for DARE to PLAY™ Sildenafil Cream, a groundbreaking topical formulation for women's arousal targeted for prescription availability in Q4 2025.
The campaign leverages Rosy's platform of 250,000+ women and includes an Arousal Collection and educational "Quickie" videos featuring expert Dr. Sameena Rahman. The product contains sildenafil (Viagra's active ingredient) and is clinically proven to improve genital blood flow and sexual response. This collaboration marks the first phase of a broader initiative that will include healthcare provider awareness and customer support programs.
DARE to PLAY™ will be available as a compounded drug under Section 503B of the FDCA, representing a significant advancement in women's sexual health treatment backed by clinical evidence.
Daré Bioscience (NASDAQ: DARE) announced a live webinar scheduled for August 6, 2025, to showcase DARE to PLAY™, their innovative sildenafil cream for female sexual arousal. The product, containing the same active ingredient as Viagra®, is the first and only evidence-backed sildenafil cream formulation for women, designed to improve genital blood flow and sexual response.
The webinar will feature prominent sexual health experts, including Dr. Irwin Goldstein, discussing clinical evidence and the product's proprietary formulation. DARE to PLAY™ is expected to be available by prescription in Q4 2025. The event, hosted in collaboration with The National Association of Nurse Practitioners in Women's Health, is open to clinicians, investors, and women interested in science-based sexual health solutions.
Daré Bioscience (NASDAQ: DARE) announced positive interim Phase 3 results for Ovaprene®, their investigational hormone-free monthly intravaginal contraceptive. The Data Safety Monitoring Board recommended continuing the study without modifications after reviewing safety data.
Key interim findings show a 9% pregnancy rate among treated women, aligning with pre-pivotal study expectations. While 17% of participants discontinued due to vaginal odor, no serious safety concerns were identified. The ongoing multicenter study targets 250 participants for 12-month use evaluation.
Bayer holds rights to obtain exclusive U.S. commercialization through a $20 million payment post-trial completion, with potential earnings of up to $310 million in commercial milestones plus double-digit tiered royalties.
Daré Bioscience (NASDAQ: DARE) has received a $6 million non-dilutive grant installment for developing DARE-LARC1, bringing the total received to $37.8 million of a $49 million commitment. DARE-LARC1 is a preclinical-stage long-acting reversible contraceptive utilizing their intelligent drug delivery system (DARE-IDDS) platform.
The DARE-IDDS platform, originally developed at MIT, features wireless control, precision dosing, and extended duration capabilities. The technology can deliver hundreds of individualized doses over months or years without recharging. Beyond contraception, the platform shows potential applications in obesity, diabetes, and other chronic conditions requiring precise, long-term dosing.
The company is actively exploring strategic partnerships to expand the platform's use beyond reproductive health, with $11.2 million in additional non-dilutive funding available upon achieving specific milestones.
Daré Bioscience (NASDAQ: DARE), a biopharmaceutical company focused on women's health, has scheduled its Q1 2025 financial results and company update conference call for May 13, 2025, at 4:30 p.m. Eastern Time. Investors can access the call via phone at (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free) using conference ID 3461324. A live webcast will be available on the company's investor relations website, with replay access until May 27, 2025.